Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter: Amylyx ...
Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.
They have at least one thing in common: An exciting pipeline.
Innovative Pharmaceutical Biotech (HK:0399) has released an update. Innovative Pharmaceutical Biotech Limited has entered into a Memorandum of Understanding to potentially acquire a majority stake in ...
Three mid-cap biotechs have become prime acquisition targets, but only one offers what big pharma is hunting for most.
Biotech investors are finally getting something they haven't seen in years: a friendlier macro environment. Interest rates appear to be stabilizing, FDA activity is picking up again, and large ...
Biotechnology stocks are wrapping up 2025 on a high note, bouncing back from a rocky start to deliver some of the year’s most impressive gains. What began as a sector weighed down by tariff fears and ...
X4 Pharmaceuticals is rated BUY, driven by a funded Phase 3 trial, current product pipeline, and a strong cash position extending into 2028. XFOR's primary value lies in its 4WARD Phase 3 trial in ...
DUBLIN--(BUSINESS WIRE)--The "Manufacturing and Supply Deals in Pharmaceuticals and Biotechnology 2020-2025" has been added to ResearchAndMarkets.com's offering. This report contains a comprehensive ...
table { width: 100%; border-collapse: collapse; font-family: Arial, sans-serif; font-size: 14px; } th, td { padding: 8px; text-align: left; } th { background-color ...
Australian pharmaceutical and biotechnology start-ups are already looking to take their investments to jurisdictions ...
Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results